MISSISSAUGA, Ontario, June 29 /PRNewswire-FirstCall/ -- CardioGenics Holdings Inc. (OTC Bulletin Board: CGNHD), developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced that Professors Robert Roberts and William J. Kostuk are the first two members to join the Company's Scientific Advisory Board. Biographical information for Drs. Roberts and Kostuk is detailed below.
Dr. Robert Roberts, MD, FRCPC, MACC
President, Chief Executive Officer and Chief Scientific Officer
University of Ottawa Heart Institute
Dr. Roberts received his M.D. from Dalhousie University and completed his residency in Internal Medicine and Fellowship in Cardiology at the University of Toronto. Funded by a Canadian Heart Foundation Scholarship he pursued research in enzymology and cardiac metabolism at the University of California, San Diego, following which he was Director of the Cardiac Care Unit at Barnes Hospital and Associate Professor of Medicine, Washington University. In 1982, he assumed the position as Chief of Cardiology at Baylor University Medical Center. Dr. Roberts was appointed as President, Chief Executive Officer and Chief Scientific Officer of the University of Ottawa Heart Institute on April 1st, 2004. http://www.ottawaheart.ca/about_us/management_team.htm
Dr. William J Kostuk, MD, FRCPC, FACC
Emeritus Professor of Medicine
University of Western Ontario
Dr. William J. Kostuk graduated from the University of Western Ontario in 1965. He did his post-graduate training in Internal Medicine and Cardiology at Western, the University of Toronto and the University of California, San Diego. He joined the faculty of Medicine at the University of Western Ontario in 1972. He served as Chief of Cardiology at University Hospital in London from 1979 to 1996 and was the Chair of the Division of Cardiology from 1986 to 1996 and now is Emeritus Professor of Medicine in the Department of Medicine. His clinical and research interests have been in ischemic heart disease, coronary intervention, cardiac transplantation and heart failure.
"We are extremely pleased to have Professors Roberts and Kostuk as members of the Scientific Advisory Board for CardioGenics Holdings," stated Dr. Yahia Gawad, Chief Executive Officer of CardioGenics. "Having two such highly regarded cardiologists on our Scientific Advisory Board is quite an honor for our company and will enable us to draw upon their valuable expertise as we move forward with the commercialization of our cardiovascular tests for the QL Care™ Analyzer," continued Dr. Gawad.
About CardioGenics Holdings Inc.
Through its operating subsidiaries, the Company develops ultra-sensitive analyzers and other products targeting the immunoassay segment of the Point-Of-Care IVD testing market. It has developed the QL Care™ Analyzer, a proprietary and ultra-sensitive Point-Of-Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's principal offices are located in Mississauga, Ontario, Canada. For more information please visit www.cardiogenics.com.
Safe Harbor Statement - Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as "anticipate, "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify forward-looking statements. These statements are based on the Company's beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company's current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company's periodic filings with the Securities and Exchange Commission.
SOURCE CardioGenics Holdings Inc.